H. Kawazoe

GSK-3 IS A POTENTIAL THERAPEUTIC TARGET FOR THE TREATMENT OF RENAL CELL CARCINOMA (RCC): PRECLINICAL IN VITRO AND IN VIVO INVESTIGATION

M. Oya, V. Bilim, Y. Tomita, 2009 .

Sequential molecularly targeted drug therapy including axitinib for a patient with end‐stage renal failure and metastatic renal cell carcinoma

Y. Tomita, Tomoyuki Kato, A. Yamagishi, 2016, Hemodialysis international. International Symposium on Home Hemodialysis.

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma

M. Oya, V. Bilim, Y. Tomita, 2009, British Journal of Cancer.

Expression of total and phospho 4EBP1 in metastatic and non-metastatic renal cell carcinoma

O. Ichiyanagi, Hiromi Ito, N. Tsuchiya, 2019, Oncology letters.

[CEREBRAL VENOUS SINUS THROMBOSIS IN PATIENTS WITH METASTATIC TESTICULAR CANCER DURING CHEMOTHERAPY: REPORTS OF TWO CASES].

O. Ichiyanagi, N. Tsuchiya, Tomoyuki Kato, 2017, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma

O. Ichiyanagi, N. Tsuchiya, Tomoyuki Kato, 2019, Scientific Reports.

GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC).

V. Bilim, Y. Tomita, Tomoyuki Kato, 2012, Biochemical and biophysical research communications.

Effect of general self-efficacy on promoting health-related quality of life during recovery from radical prostatectomy: a 1-year prospective study

N. Tsuchiya, Tomoyuki Kato, T. Konta, 2020, International Journal of Clinical Oncology.

[Extracorporeal partial nephrectomy and auto-transplantation after presurgical targeted therapy with tyrosine kinase inhibitors for renal cell cancer].

Y. Tomita, M. Yamakawa, Tomoyuki Kato, 2013, Hinyokika kiyo. Acta urologica Japonica.

Risk factors for erectile dysfunction in end-stage renal disease patients with short- or long-term hemodialysis therapy

Y. Tomita, O. Ichiyanagi, N. Tsuchiya, 2016, Renal Replacement Therapy.